France Updates List of Pharmaceuticals Approved for Public Services
An order dated October 26, 2026, signed by the French Ministers of Health and Public Accounts, modifies the list of pharmaceutical specialties approved for use by public institutions and various public services. This update follows a favorable opinion from the Haute Autorité de santé's transparency commission regarding the reimbursement of the reference specialty ZYTIGA®. The changes will be published in the Official Journal of the French Republic.
What does it mean?
France has updated its official list of medicines that public institutions can use. This change includes the drug ZYTIGA®, which is now approved for reimbursement by public health services after a health authority review. The updated list will be published in the official government gazette.
Who is affected?
Public institutions and healthcare providers using approved pharmaceutical specialties.
What changes?
The list of pharmaceutical specialties approved for use by public institutions and various public services has been modified.